A little-known biotech’s high-stakes cancer bet just paid off and its shares doubled
Genmab’s shares have doubled in three months after a string of cancer drug trial wins, strengthening its push to own more of the medicines it develops.
Ringkasan berita
Genmab’s shares have doubled in three months after a string of cancer drug trial wins, strengthening its push to own more of the medicines it develops.
Ikuti berita terbaru dari penerbit tepercaya dengan ringkasan singkat. Buka tautan sumber asli untuk detailnya.